---
schema_version: "secwatch.filing_event.v1"
accession: "0001630627-26-000017"
form_type: "8-K"
ticker: "TMCI"
cik: "0001630627"
company_name: "TREACE MEDICAL CONCEPTS, INC."
filed_at: "2026-08-07T11:10:15+00:00"
generated_at: "2026-08-07T11:15:19.394701+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Treace Q2 2026 revenue $45.4M (-4% YoY), net loss $15.9M, raises FY guidance

## Summary
- Q2 2026 revenue $45.4M vs $47.4M in Q2 2025 (-4%); net loss $(15.9)M or $(0.24)/share.
- Adjusted EBITDA loss $(3.5)M, improved from $(3.6)M; gross margin 78.5% vs 79.7%.
- Cash usage cut 57% YoY; cash and securities $45.6M at June 30, 2026.
- FY 2026 revenue guidance raised to $204-212M (from $202-212M); EBITDA loss narrowed to $3-5M.
- New products: SuperBite Screw System launched, HyperPlate XM first case; 40% of surgeons use new bunion systems.

## SEC filing metadata
- accession: 0001630627-26-000017
- form_type: 8-K
- ticker: TMCI
- cik: 0001630627
- company_name: TREACE MEDICAL CONCEPTS, INC.
- filed_at: 2026-08-07T11:10:15+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1630627/000163062726000017/0001630627-26-000017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1630627/000163062726000017/tmci-20260807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001630627-26-000017
- JSON: https://secwatch.observer/filing/0001630627-26-000017.json
- Plain text: https://secwatch.observer/filing/0001630627-26-000017.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.